Fold №45 — Retatrutide Lys-40 γGlu-C18 Diacid C-terminal Lipidation

Verdict: PROMISING | pLDDT 0.70 | Class: METABOLIC | Target: GLP-1R / GIPR / GCGR

Mechanism of Action

Retatrutide is a 39-residue synthetic triple agonist that co-activates the glucagon-like peptide-1 receptor (GLP-1R, UniProt P43220), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This tri-agonism produces complementary metabolic effects: GLP-1R engagement drives insulin secretion and appetite suppression; GIPR co-activation amplifies insulin release and may modulate adipose lipid mobilization; GCGR activation increases hepatic glucose output and energy expenditure. The combination yields the largest body weight reductions observed in any incretin-based pharmacotherapy — 22–24% at 48 weeks in Phase 2 trials, exceeding semaglutide and tirzepatide.

The native molecule incorporates a Lys-20 fatty acid conjugate that enables reversible binding to human serum albumin (HSA), extending plasma half-life from minutes (unmodified peptide) to approximately one week — sufficient for once-weekly subcutaneous dosing. The C-terminal PPPS sequence is proline-rich and predicted to be conformationally disordered, analogous to the C-terminal extension of exendin-4, which does not participate in receptor binding.

Modification Rationale

Fold №45 appends a single Lys residue (Lys-40) to the C-terminus of the native PPPS tail, bearing a γ-glutamate (γGlu) spacer conjugated to a C18 fatty diacid (octadecanedioic acid) on the ε-amine. The complete modification is: ...PPPS-K(γGlu-C18-diacid)-OH.

The design rationale rests on three principles:

1. Spatial decoupling of albumin anchor from receptor-binding face. The native Lys-20 lipidation sits within the central amphipathic helix — the same structural element that engages GLP-1R, GIPR, and GCGR extracellular domains. Placing a second lipid anchor at the disordered C-terminal tail is predicted to provide additional albumin binding capacity without perturbing helical geometry or introducing steric clash at the receptor interface.

2. Validated chemistry. The γGlu-C18 fatty diacid motif is the semaglutide-class albumin-binding scaffold, with well-characterized pM–nM HSA affinity at Sudlow site II. This choice is directly supported by Fold №36 (Semaglutide β-Ala-β-Ala spacer substitution, DISCARDED), which demonstrated that departure from the γGlu spacer architecture compromises albumin binding signal — reinforcing that the γGlu linker retained here is the pharmacologically optimal choice.

3. PK extension hypothesis. If a second albumin anchor increases overall HSA affinity additively or synergistically with the native Lys-20 anchor, the result could be an extended effective half-life enabling less-frequent dosing (e.g., biweekly) — a clinically and commercially meaningful advance if the receptor bioavailability of free peptide is maintained.

This fold is distinct from the recent Retatrutide series: Fold №10 (Lys-17 → Arg, helix stability focus), Fold №34 (Tyr-13 → 2-Nal, selectivity bias), and Fold №3 (Aib-2, DPP-4 resistance) all targeted the receptor-engaging core sequence. Fold №45 is the first in the lab's Retatrutide series to target pharmacokinetics via lipidation chemistry — complementing those structural modifications with a PK axis.

Predicted Properties — Where the Signal Is Moderate

Confidence note: All values are computational estimates. The heuristic half-life does not model albumin-binding kinetics from the C18 diacid — actual PK would require SPR measurement of HSA affinity and in vivo pharmacokinetic studies. The pTM (0.61) and ipTM (0.27) reflect monomer prediction artifacts and should not be interpreted as binding affinity metrics.

What Would Strengthen This Signal

Computational next steps:

• Ensemble prediction: Run 5+ independent AlphaFold2/ESMFold predictions and report pLDDT variance across the helical core. A stable helix across ensemble members would substantially increase confidence in the structural interpretation.
• Molecular dynamics (MD) simulation: Model the C-terminal tail flexibility explicitly and confirm that the γGlu-C18 chain does not transiently contact the helical face over ns–µs timescales — the static structure prediction cannot rule out dynamic intramolecular interactions.
• Docking of lipid–albumin complex: Dock the C18 diacid–γGlu moiety into the HSA Sudlow site II structure (PDB: 1BM0) in the context of the full modified peptide to estimate binding pose and predict HSA affinity relative to semaglutide's linker.
• Dual-lipidated peptide comparators: Predict structures of Lys-40(γGlu-C18) alone (no native Lys-20 lipid) and the double-lipidated variant to isolate the structural contribution of each anchor.

Wet-lab validation experiments:

• SPR/ITC: Measure HSA binding affinity (K_d) for native Retatrutide, Fold №45 variant, and semaglutide as reference. Determine whether dual-lipidation yields additive (K_d sub-nM) or diminishing-returns albumin affinity.
• In vitro receptor panel (GLP-1R, GIPR, GCGR cAMP assay): Confirm that Lys-40 lipidation does not impair EC₅₀ at any of the three receptors, particularly GCGR where C-terminal peptide contacts may be relevant.
• Pharmacokinetic study (rodent or NHP): Compare half-life, AUC, and subcutaneous bioavailability of native Retatrutide vs. Fold №45 variant. The key outcome is whether t₁/₂ is meaningfully extended beyond ~7 days.
• Aggregation assay: Measure critical aggregation concentration (CAC) by ThT fluorescence and DLS at 1–100 µM to confirm low aggregation propensity at therapeutically relevant depot concentrations.
• GCGR-specific activity: Given that glucagon's C-terminal region contributes to GCGR selectivity, assess whether the C-terminal Lys-40 extension alters GCGR potency specifically relative to GLP-1R and GIPR.

Lab Context and Cross-Fold Connections

This fold builds directly on the Retatrutide series:

• Fold №10 (Lys-17 → Arg, pLDDT 0.78, PROMISING) established that point mutations in the central helix of Retatrutide preserve helical integrity — providing a high-confidence structural baseline for interpreting the Fold №45 helix at pLDDT 0.70.
• Fold №34 (Tyr-13 → 2-Nal, pLDDT 0.64, PROMISING) showed that even a bulky non-canonical substitution within the receptor-binding face is tolerated structurally, suggesting the scaffold is robust — but also raising the question of whether two concurrent perturbations (Tyr-13 + Lys-40 lipidation) would be additive or compounding.
• Fold №36 (Semaglutide β-Ala-β-Ala spacer, DISCARDED) is the most directly informative precedent: it demonstrated that departing from the γGlu spacer architecture for a C18 diacid conjugate produces a weaker structural signal. Fold №45 retains the γGlu spacer precisely because of this finding — a clear example of negative-result learning driving design.
• Fold №3 (Retatrutide Aib-2, DISCARDED) explored DPP-4 resistance and is orthogonal to this PK-focused fold, but suggests that the N-terminus of Retatrutide is an independent optimization axis that could be combined with C-terminal lipidation in a future dual-modification variant.

Disclaimer: All findings are in silico predictions only. No wet-lab experiments have been performed. Predicted properties do not constitute evidence of biological activity. This is exploratory computational research, not medical advice.